Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome

Cancer

Volumn 86, Issue 4, 1999, Pages 684-688

  Edelman, Martin J ^a,b,c,d   Gandara, David R ^a,b   Meyers, Frederick J ^a   Ishii, Rie ^a   O'Mahony, Michael ^a   Uhrich, Margaret ^a   Lauder, Ignacio ^b   Houston, Joan ^a   Gietzen, Dorothy W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c DAVID GRANT MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Cancer cachexia; Ondansetron; Serotonergic blockade; Type 3 serotonin receptors

Indexed keywords

ALBUMIN; ONDANSETRON; PREALBUMIN; RETINOL; RETINOL BINDING PROTEIN; SEROTONIN ANTAGONIST;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID SEQUENCE; ANOREXIA; ANTHROPOMETRY; ARTICLE; CACHEXIA; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; GRIP STRENGTH; HAND GRIP; HUMAN; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; SEROTONINERGIC NERVE CELL;

ADULT; AGED; ANOREXIA; CACHEXIA; DIETARY PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NUTRITIONAL STATUS; ONDANSETRON; SEROTONIN ANTAGONISTS; WEIGHT LOSS;

EID: 0033566970     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990815)86:4<684::AID-CNCR18>3.0.CO;2-6     Document Type: Article

References (30)

1. Tisdale MJ. Cancer cachexia. Br J Cancer 1992;63(3):337-42.
2. Leibowitz SF, Weiss GF, Shor-Posner G. Hypothalamic serotonin: pharmacological, biochemical and behavioral analyses of its feeding suppressive action. Clin Neuropharmacol 1988;11(1 Suppl):S51-71.
3. Krause R, James JH, Ziparo V, Fisher JE. Brain tryptophan and the neoplastic anorexia-cachexia syndrome. Cancer 1979;44:1003-8.
4. Fanelli FR, Cangiano C, Ceci F, Cellerino R, Franchi F, Menichetti ET, et al. Plasma tryptophan and anorexia in human cancer. Eur J Cancer Clin Oncol 1986;22:89-95.
5. Naini AB, Dickerson JWT, Brown M. Preoperative and postoperative levels of plasma protein and amino acid in esophageal and lung cancer patients. Cancer 1988;62:355-60.
6. Gietzen DW, Hammer VA, Beverly JL, Rogers QR. The role of serotonin (5HT) in feeding responses to amino acids. In: Schwarcz R, et al., editors. Kynuremine and serotonin pathways. New York: Plenum Press, 1991:389-94.
7. Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RS, et al. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol 1991;9:1268-74.
8. Marion Merrell Dow Inc. Protocol 73,147-1-C-019. A double-blind placebo-controlled, single dose-rising tolerance study of oral MDL 73, 147EF in normal volunteers. Data on file.
9. Vie A, Gulli D, O'Mahony M. Alternative hedonic measures. J Food Sci 1991;56:1-5, 46.
10. Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762-7.
11. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11: 152-4.
12. Rowland KM, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 1996;14:135-41.
13. Beller E, Tattersall M, Lumley T, Levi J, Dalley D, Oliver I, et al. Improved quality of life with megestrol acteate in patients with endocrine insensitive advanced cancer: a randomized placebo controlled trial. Australasian Megestrol Acetate Study Group. Ann Oncol 1997;8:277-83.
14. Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megesterol acetate in patients with AIDS. Ann Intern Med 1995;122:843-5.
15. Simons JP, Schols AMWJ, Hofnagels JMJ, Westerterp KR, ten Velde GPM, Wouters EFM. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, non-hormone sensitive cancer. Cancer 1998;82:553-60.
16. Loprinzi CL, Kuross SA, O'Fallon JR, Gesme DH, Gerstner JB, Rospond RM, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994;12:1121-5.
17. Goldberg RM, Loprinzi CL, Mailliard JA, O'Fallon JR, Krook JE, Ghosh C, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995;13:2856-9.
18. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 1989;25:1823-9.
19. Beal JA. Appetite effect of dronabinol. J Clin Oncol 1994;12: 1524.
20. Williams LR, Cohen MH. Altered taste thresholds in lung cancer. Am J Clin Nutr 1978;31:122-5.
21. DeWys WD, Walters K. Abnormalities of taste sensation in cancer patients. Cancer 1975;36:1888-96.
22. Kamath S, Booth P, Lad TE, Kohrs MB, McGuire WP. Taste thresholds of patients with cancer of the esophagus. Cancer 1983;52:386-9.
23. O'Mahony M. Understanding discrimination tests: a user friendly treatment of response bias, rating and ranking R-index tests and their relationships to signal detection. J Sensory Stud 1992;7:1.
24. Gietzen DW, Erecius LF, Rogers QR. Neurochemical changes after imbalanced diets suggest a brain circuit mediating anorectic responses to amino acid deficiency in rats. J Nutr 1998;128:771-81.
25. Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR. Selective 5-Hydroxytryptamine Type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992;67: 732-8.
26. Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy: dose, schedule and route of administration. Support Care Cancer 1998;6:237-43.
27. Italian Group for Antiemetic Research. Difference in the persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993;11: 2396-404.
28. McNamara MJ, Alexander HR, Norton JA. Cytokines and their role in the pathophysiology of cancer cachexia. JPEN 1992;16:50S-5S.
29. Espat NJ, Moldawer LL, Copeland EM. Cytokine-mediated alterations in host metabolism prevent nutritional repletion in cachectic cancer patients. J Surg Oncol 1995;58: 77-82.
30. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996;379:739-42.